ArticleRheumatology (Oxford, England)2026
Differences in spinal structural lesions between patients with early axSpA and non-axSpA chronic back pain: 2-year SPACE cohort results.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo compare spinal structural lesions on radiography and magnetic resonance imaging (MRI) over 2 years, between patients with early axial spondyloarthritis (axSpA) and non-axSpA chronic back pain.
methodsPatients from the SPACE cohort with available radiography or MRI at both baseline and 2years were included. Spinal lesions on radiography were assessed by the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS), corner MRI lesions by the modified Canada-Denmark scoring system. Baseline spinal structural lesions and 2-year changes were compared between axSpA and non-axSpA. Generalized estimating equations were used to assess the change over 2 years, adjusting for age, sex, non-steroidal anti-inflammatory drug use and diagnosis.
resultsRadiography data from 318 patients (67% axSpA), MRI data from 351 patients (69% axSpA) were included. At baseline, the mean (SD) mSASSS was 0.6 (1.1) for both axSpA and non-axSpA. Over 2 years, mSASSS progression was minimal (0.01 units/year) in both groups. On MRI, axSpA patients had a mean of 1.4 (2.9) total structural lesions compared with 0.7 (2) in non-axSpA at baseline (P = 0.12). Significant 2-year increase in structural lesions [0.5 (1.8)] was mainly due to fat lesions [0.5 (1.6)] in axSpA. On MRI, fat lesions changed at a rate of 0.16 units/year in axSpA (P = 0.002) and -0.02 units/year in non-axSpA (P = 0.70).
conclusionOver 2 years, spinal structural damage typical for axSpA progressed minimally on radiography in axSpA and non-axSpA. On MRI, axSpA showed a significant increase in fat lesions, while non-axSpA had no progression. Fat lesions may be important to assess spinal changes from early disease onwards.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.